Conference item icon

Conference item

Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Abstract:
Asthma is associated with increased airway smooth muscle (ASM) mass with increased disease severity and impaired lung function. The prostaglandin D2 (PGD2) receptor 2 (DP2) antagonist, fevipiprant, reduces airway eosinophilia and improves epithelial integrity, lung function, ACQ and AQLQ.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1183/1393003.congress-2017.OA283

Authors


Saunders, R More by this author
Singapuri, A More by this author
Chernyavsky, I More by this author
Expand authors...
Publisher:
European Respiratory Society Publisher's website
Volume:
50
Issue:
S61
Pages:
Article: OA283
Publication date:
2017-12-06
DOI:
Pubs id:
pubs:871832
URN:
uri:dcd6daef-15a7-4719-9c82-e194a008bbe0
UUID:
uuid:dcd6daef-15a7-4719-9c82-e194a008bbe0
Local pid:
pubs:871832

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP